Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826)

Market Cap	12.86B
Revenue (ttm)	2.95B
Net Income (ttm)	479.41M
Shares Out	231.72M
EPS (ttm)	1.45
PE Ratio	21.71
Forward PE	12.92
Dividend	0.88 (2.80%)
Ex-Dividend Date	Sep 20, 2024

Volume	369,400
Open	31.35
Previous Close	31.40
Day's Range	30.25 - 31.35
52-Week Range	27.70 - 50.20
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai Haohai Biological Technology

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,158
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2023, Shanghai Haohai Biological Technology's revenue was 2.65 billion, an increase of 24.59% compared to the previous year's 2.13 billion. Earnings were 416.12 million, an increase of 130.58%.

Financial numbers in CNY